Vincristine Sulfate
Mixed Phenotype Acute Leukemia
Explore 67 assets in Mixed Phenotype Acute Leukemia →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05761171CT.gov A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | — | Active Not Recruiting | — | — | — |
NCT03959085CT.gov Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | — | Recruiting | — | — | — |
NCT03007147CT.gov Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02828358CT.gov Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | — | Completed | — | — | — |
NCT02135874CT.gov Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mixed Phenotype Acute Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vincristine Sulfate (this asset) | Children's Oncology Group | P3 | B · 59 |
| Daunomycin | St. Jude Children's Research Hospital | P4 | BB |
| Dexasone | St. Jude Children's Research Hospital | P4 | BB |
| Cytarabine | Children's Oncology Group | P4 | BB |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
| Hydrocortisone | Children's Oncology Group | P4 | BB |
| Treosulfan | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P2/3 | BB |
| Methotrexate | Children's Oncology Group | P4 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P3 | B |
+42 more in the Mixed Phenotype Acute Leukemia cohort
Other indications for Vincristine Sulfate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | A · 81 |
| Diffuse Large B-Cell Lymphoma | — | P2/3 | A · 80 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vincristine Sulfate in Mixed Phenotype Acute Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-sulfate-mixed-phenotype-acute-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →